Schistosomiasis medical therapy

Revision as of 18:44, 18 September 2017 by WikiBot (talk | contribs) (Changes made per Mahshid's request)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Schistosomiasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Schistosomiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Schistosomiasis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Schistosomiasis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Schistosomiasis medical therapy

CDC on Schistosomiasis medical therapy

Schistosomiasis medical therapy in the news

Blogs on Schistosomiasis medical therapy

Directions to Hospitals Treating Schistosomiasis

Risk calculators and risk factors for Schistosomiasis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

The mainstay of treatment for schistosomiasis is pharmacotherapy. Praziquantel is the drug of choice in treating schistosomiasis. Corticosteroids should be administered in addition to praziquantel in patients with symptoms due to neuro-schistosomiasis and patients with severe katayama fever. The goals of treatment of schistosomiasis are to eradicate the helminth and correct any sequelae of infection. While praziquantel is safe and highly effective in curing an infected patient, it does not prevent re-infection by cercariae and is thus not an optimum treatment for people living in endemic areas.

Medical Therapy

Antimicrobial Regimen

  • 1. Schistosoma mansoni, S. haematobium, S. intercalatum[1]
  • Preferred regimen: Praziquantel 40 mg/kg per day PO in qd or bid for one day
  • Alternative regimen (1): Oxamniquine 20 mg/kg PO single dose[2][3]
  • Alternative regimen (2): Artemisinin no dose is established yet[1]
  • Alternative regimen (3): Mefloquine 250 mg PO single dose
  • Note: There is no benefit in associating the alternative therapies to praziquantel.
  • Note: Praziquantel is not effective against larval/egg stages of the disease.[4]
  • 2. S. japonicum, S. mekongi[1]
  • Preferred regimen: Praziquantel 60 mg/kg per day PO bid for one day
  • Alternative regimen (1): Artemisinin no dose is established yet
  • Alternative regimen (2): Mefloquine 250 mg PO single dose
  • Note: There is no benefit in associating the alternative therapies to Praziquantel.
  • 3. Katayama Fever

Praziquantel

  • Praziquantel is first-line therapy for infection with all five Schistosoma species.
  • Praziquantel is also used as part of mass chemotherapy campaigns in endemic areas to decrease individual worm burden.
  • Not effective against immature schistosomes (schistosomules).
  • Not useful for treatment of cercarial dermatitis (i.e, cutaneous schistosomiasis or swimmer's itch) caused by transient, self-limited infection with Austrobilharzia species.
  • Very well tolerated; adverse effects are usually mild and transient and do not require treatment.
  • Women who are breastfeeding should not breastfeed on the day of treatment.
  • Rifampin significantly reduces the bioavailability of praziquantel and, thus, should be discontinued 4 weeks before treatment.
  • Schistosome eggs may take weeks to pass out of the intestinal and bladder wall; therefore, egg passage continues for approximately a month after treatment.

Corticosteroids

Artemisinin compounds

References

  1. 1.0 1.1 1.2 Colley DG, Bustinduy AL, Secor WE, King CH (2014). "Human schistosomiasis". Lancet. 383 (9936): 2253–64. doi:10.1016/S0140-6736(13)61949-2. PMID 24698483.
  2. National Center for Biotechnology Information. PubChem Compound Database; CID=4612, https://pubchem.ncbi.nlm.nih.gov/compound/4612 (accessed July 16, 2015).
  3. BINA, J. C. and PRATA, A.. Tratamento da esquistossomose com oxamniquine (xarope) em crianças. Rev. Soc. Bras. Med. Trop.[online]. 1975, vol.9, n.4 [cited 2015-07-16], pp. 175-178 . Available from: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86821975000400002&lng=en&nrm=iso>. ISSN 0037-8682. http://dx.doi.org/10.1590/S0037-86821975000400002.
  4. Paramythiotou E, Frantzeskaki F, Flevari A, Armaganidis A, Dimopoulos G (2014). "Invasive fungal infections in the ICU: how to approach, how to treat". Molecules. 19 (1): 1085–119. doi:10.3390/molecules19011085. PMID 24445340.
  5. Jauréguiberry S, Paris L, Caumes E (2010). "Acute schistosomiasis, a diagnostic and therapeutic challenge". Clin Microbiol Infect. 16 (3): 225–31. doi:10.1111/j.1469-0691.2009.03131.x. PMID 20222897.
  6. Jauréguiberry S, Paris L, Caumes E (2009). "Difficulties in the diagnosis and treatment of acute schistosomiasis". Clin Infect Dis. 48 (8): 1163–4, author reply 1164-5. doi:10.1086/597497. PMID 19292640.